The conversation is about a user experiencing hair loss who has been using finasteride for a year and minoxidil once a day for five months, but still experiences shedding and thin hair. The user is considering switching to dutasteride next year and shares their progress with others using similar treatments.
The conversation discusses whether to wait for Breezula while using topical minoxidil to avoid side effects from finasteride. It mentions Breezula's potential release in a year and its cost and long-term use considerations.
A user is curious why their DHT levels are not higher despite using 400mg of testosterone without finasteride, and wonders if zinc or GHK-Cu injections could be influencing this. Another user suggests that more testosterone typically leads to more DHT, but the user might be fortunate not to exceed normal DHT levels.
OP experienced erectile dysfunction after taking a 0.5 mg dutasteride capsule for hair loss and is considering switching to finasteride. A user suggested consulting a dermatologist and possibly trying topical treatments if side effects persist.
The user is starting dutasteride mesotherapy and seeks information on checking serum DHT levels in Germany. They previously tried finasteride but experienced unpleasant side effects.
A user is considering a hair transplant in a "mohawk" pattern with scalp micropigmentation (SMP) on the sides and back, questioning its feasibility and appearance. Others discuss donor region quality, potential scarring, and alternative treatments like dutasteride and RU58841.
Switching from tretinoin to tazarotene with minoxidil led to new hair regrowth after years of maintenance. Tazarotene's selectivity and higher concentration might be more effective for hair growth.
Low testosterone and estradiol may contribute to hair loss, and blocking DHT without sufficient hormone levels might hinder regrowth. The discussion highlights the importance of hormone balance, with some considering supplements and lifestyle changes to support hair health.
The conversation is about the effectiveness of topical azelaic acid in blocking DHT for hair loss treatment. Specific treatments discussed include Minoxidil, finasteride, and RU58841.
A 30-year-old male switched from finasteride to a combination of dutasteride, oral minoxidil, and RU58841, achieving significant hair growth without side effects. He plans to add GHK-Cu peptide to his regimen for further improvement.
People who have not responded to finasteride (Fin) switching to dutasteride for hair loss treatment and their experiences with the switch. Other treatments such as Minoxidil (Min) and RU58841 are also discussed.
The user switched from finasteride to dutasteride while on TRT to protect against hair loss but is experiencing thinning hair. They are unsure if the issue is due to dutasteride or TRT.
An 18-year-old male switched from topical finasteride and minoxidil to oral dutasteride for diffuse hair loss and saw improvement without side effects, despite experiencing scalp itch and shedding. Commenters noted significant hair regrowth and were surprised by his young age and appearance.
A 57-year-old man with male pattern hair loss and insulin resistance experienced hair regrowth and weight loss after using tirzepatide, without other hair treatments. Dysregulated glucose metabolism is linked to hair loss, with tirzepatide potentially improving hair density by normalizing insulin resistance.
The conversation discusses the potential for developing a biologic "DHT sponge" to neutralize DHT in the bloodstream as a treatment for hair loss, suggesting it could be more targeted and have fewer side effects than current treatments like finasteride and dutasteride. Concerns include the complexity, cost, and potential side effects of such a treatment, as well as skepticism about its feasibility and market interest.
The conversation is about finding a safe carrier for topical antiandrogens like finasteride, kx-826, RU58841, and dutasteride to minimize systemic absorption and side effects. The user experiences side effects from these treatments and is seeking advice on carriers that reduce these effects.
A 20-year-old is considering switching from applying a Minoxidil 5%/Finasteride 0.1% solution twice daily to once daily due to cost and convenience. It is suggested that applying once a day before sleep should still be effective if done consistently.
User experienced hair growth with finasteride and minoxidil, but after using tretinoin, faced aggressive thinning and hair loss. They plan to stop tretinoin for two months to see if the problem improves.
The conversation is about the potential format of Breezula, a hair loss treatment, and concerns that it might be greasy or sticky. Specific treatments mentioned are Minoxidil, finasteride, and RU58841.
The DNA Trichotest is considered unreliable for predicting hair loss treatment responses, and topical spironolactone is questioned for its effectiveness and safety in cis males. Finasteride and Dutasteride are recommended as more reliable treatments for androgenic alopecia.
A user has been using finasteride and minoxidil for hair loss without success and is considering switching to dutasteride. They are concerned about low DHT levels and are seeking advice on how to implement dutasteride effectively.
A 19-year-old male experienced significant hair loss, initially thought to be male pattern baldness (MPB), and used minoxidil and briefly finasteride. After realizing the issue was telogen effluvium (TE), he improved his diet and supplemented with vitamins, which led to substantial hair regrowth.
The conversation discusses a transgender individual's successful hair loss treatment over 1.5 years using 2.5mg oral minoxidil, 5mg finasteride, and 8mg weekly injectable estradiol valerate. Some users debate the appropriateness of this approach within the group's goals, while others support the individualized treatment and its additional benefits for transgender individuals.
User quit minoxidil and finasteride, starting stemoxydine, dermastamp, and dermapen for hair loss. Seeks advice on alternatives, avoiding androgen disruptors and vasodilators/vasoconstrictors.
Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.
A user, 18, is considering switching from topical finasteride (0.025%) and minoxidil to dutasteride due to continued hair shedding. Other users shared their experiences with dutasteride, noting potential benefits and risks, including reduced sperm count.
The user is considering using Minoxidil and Tretinoin to manage hair loss while waiting for Breezula/PP405, as they cannot tolerate dutasteride or finasteride. They hope these treatments will help retain hair despite ongoing loss.